Client workspace

Enterprise Discovery Workspace

Static fallback Signed out
Public demonstration dataset. This console is populated from the validated B000 HPC demonstration using two tiny public biomedical records. It is ready for end-user walkthroughs, not clinical decision-making or production client data processing.

Executive summary

KRAS G12C translational strategy is export-ready for scientific review.

A unified evidence run connected molecular testing, therapy selection, resistance monitoring, and trial-matching signals into one boardroom-ready recommendation.

94% AI confidence
Evidence Trust Score 96 / 100 source mix · recency · review status

Strategic Recommendation

Adopt reflex KRAS G12C testing for eligible NSCLC workflows.

Connect mutation confirmation with therapy eligibility, resistance surveillance, and clinical-trial routing.

Business Impact

Shorten evidence review cycles.

Turn scattered publications, labels, and trial records into a traceable recommendation package.

Scientific Confidence

High confidence, review complete.

Evidence is supported by regulatory, literature, trial, and ontology-backed sources.

Risk

Research-use boundary maintained.

Public demonstration dataset only; no PHI and no clinical decision automation.

Workspace focus

Executive only view

Portfolio metrics, source charts, review statistics, observability, and project hierarchy are now organized in the Analytics workspace to keep this first screen focused on the decision.

Portfolio command center

Enterprise discovery portfolio

Governance validated
Active projects4
Completed discoveries27
Review backlog6
HPC utilization41%
Cloud readinessPrepared
Deployment statusValidated demo

Top discovery

KRAS G12C biomarker strategy

94%

A KRAS G12C-focused molecular testing strategy links NSCLC patient selection, resistance monitoring, targeted therapy evidence, and trial-routing decisions.

18 publications 4 trials 2 biomarkers 98% validation
BioDiscoveryAI KRAS G12C NSCLC Translational Intelligence Report Research use only · Public demonstration dataset
  1. Executive Summary
  2. Scientific Findings
  3. Evidence Summary
  4. Review & Governance
PDF Word
Suggested action Prioritize KRAS G12C reflex molecular testing and route resistance hypotheses for expert review.

Multi-project management

Portfolio to discovery hierarchy

4 active programs
PortfolioProgramProjectCaseDiscovery
Oncology Precision MedicineKRAS G12C · EGFR resistance · ALK fusion
Translational Evidence OperationsSource monitoring · review queue · export packages
Governance ReadinessAudit trail · SSO readiness · retention controls

Saved dashboards

Personalized executive views

Multi-user workspace

Active collaborators

Shared session
NC Dr. Chen · reviewing AP Dr. Patel · evidence request NA Nabil · presenter
Report export locked while scientific review decision is open.
Biomedical Records2
Evidence Nodes1,247
Hypotheses14
AI Confidence94%
Runtime3m 12s
GovernanceValidated

Evidence by source

Source coverage

PubMed FDA Trials OpenTargets

Hypothesis confidence

Distribution

Publication timeline

Evidence over time

Review statistics

Decision flow

2 approvals1 evidence request0 blockers

Disease map

Signal heatmap

Project velocity

Discovery throughput

Workflow visualization

Discovery pipeline

Demonstration active
Data Intake -> Extraction -> Knowledge Graph -> AI Reasoning -> Ranking -> Scientific Review -> Deployment
72% Evidence Graph running...
B004 Intake · Completed B005 Extraction · Completed B006 Graph · Running B007 Ranking · Queued

Knowledge graph

Biology-aware relationships

86 relationships
KRAS KRAS G12C NSCLC sotorasib adagrasib Clinical trials Evidence
Select a node to inspect evidence, confidence, and provenance.

AI reasoning

Why this ranked first

92%

Top hypothesis: KRAS G12C tumors may benefit from a biomarker-confirmed therapy-selection strategy that includes resistance monitoring and trial matching.

  1. Detect KRAS G12C and NSCLC disease context.
  2. Map therapies, trials, and resistance evidence.
  3. Score source strength, recency, and clinical relevance.
  4. Route the ranked hypothesis to scientific review.
PubMed3 studies
ClinicalTrials2 trials
OpenTargets1 association
Contradicting evidence1 study
Model/versionOpenAI RAG · demo
Reviewer decisionApproved with evidence

Evidence provenance explorer

Hypothesis to source traceability

Drilldown path
-> -> -> ->
Selected evidence statement

KRAS G12C status supports targeted therapy selection in advanced NSCLC when aligned with regulatory labels, molecular testing, and clinical-trial eligibility evidence.

Open PubMed provenance search

Scientific metrics

Discovery content

Genes 12 Variants 4 Drug targets 8 Clinical trials 4 Evidence nodes 1,247 Relationships 86 Pathways 9 Biomarkers 6

Evidence quality

Trusted source coverage

★★★★★
PubMedFDAClinicalTrialsOpenTargetsCOSMICNCCNESMOOncoKB

Scientific review

Ready for export

98%

3 reviewers · 2 approvals · 0 concerns

Export ready

Execution timeline

Enterprise trace

  1. Intake
  2. Extraction
  3. Graph
  4. Ranking
  5. Review
  6. Completed

Run duration

Execution environment

Started 09:32 Finished 09:37 Elapsed 5m 18s CPU 32 Memory 64 GB Environment Explorer HPC Queue wait 18s GPU usage 0% Failed modules 0 Retries 0 Nextflow 25.04.6 Container Apptainer

Collaboration layer

Review assignments and approvals

Review complete
Reviewer assigned

Dr. Chen · Translational Oncology · due Friday 4:00 PM

Dr. Chen

@oncology-review Evidence supports therapy-selection strategy. Approved.

Decision history: accepted with evidence · e-signature CHEN-20260628
Dr. Patel

Request follow-up on resistance-marker panel before pilot expansion.

Thread reply required · assigned to Biomarker Lead
Approval chain

Scientific Reviewer -> Biomarker Lead -> Governance Officer -> Export Owner

Platform Admin

Electronic approval captured with audit event and report hash.

Enterprise identity and security

Access boundary

Policy enforced
SSO status OIDC ready Tenant demo-tenant User role Scientific reviewer MFA Required in production Audit session RUN_20260627 Data policy Public demo only

Current run

Workflow status

PASS
Pipeline Modules 8
Execution Artifacts 377
Validated Artifacts 377
Runtime HPC

Run narrative

Tiny biomedical records were governed through runtime checks, source intake, extraction, graph construction, hypothesis generation, and review governance.

No client dataset selected

Sample input

Biomedical source records

Demo Dataset

Module chain

Validated execution path

Question to report

KRAS G12C NSCLC translational intelligence

Public data only

Benchmark set

50 pilot questions

0 loaded

Workflow Orchestration

Knowledge workflow

Execution log

Latest events

Remote exit 0

    Evidence browser

    Artifacts and validation

    Module Task Reports Validated Artifacts Status

    Expert review

    Prioritized hypotheses

    Scientific case

    KRAS G12C - NSCLC - Biomarker Strategy

    Research use only

    Case status

    Evidence-linked prototype

    PASS
    Records 5
    Entities 10
    Relations 86
    Hypotheses 3

    Top hypothesis

    Use reflex KRAS G12C molecular testing for advanced or metastatic NSCLC records before treatment strategy review.

    Evidence graph

    Biomarker strategy network

    0 edges

    Entities

    Normalized biomedical concepts

    Hypotheses

    Ranked strategy claims

    Production readiness

    Client rollout checklist

    Demo ready

    Ready now

    • Workflow orchestration sequence validated on HPC
    • Final summary generated with pass/fail counts
    • Containerized module execution proven
    • Evidence paths and manifests emitted

    Before client data

    • Connect UI to governance API
    • Add authentication and tenant isolation
    • Run curated representative biomedical sample
    • Complete client security review

    Operating model

    Research user Submits source package and reviews hypotheses.
    Governance owner Audits manifests, task reports, and decision trail.
    Platform operator Runs workflow orchestration on HPC and manages containers and storage.

    Admin settings

    Runtime configuration

    User lifecycle

    Access model

    Loading

    Compliance boundary

    Data governance

    Review

    Operations

    Monitoring and cost

    Loading

    Recent activity

    System log

    0 events

    Reusable platform

    Biomedical foundation model

    External validation required

    Projects and schemas

    General project contract

    0 schemas

    Evidence Intake

    Supported input formats

    0 formats

    Scientific configuration

    Ontology and scoring

    Ready

    Production adapters

    Postgres and HPC validation

    Not validated here